Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Stockerau – page 57

880 clinical trials in Stockerau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Stockerau at a glance
880
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

880 trials in Stockerau

Open in trial search

Polycythaemia vera

Not recruiting

Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carbasalate Calcium
  • Sponsor:Italfarmaco S.p.A.

Breast cancer

Not recruiting

Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Hypophosphatasia

Not recruiting

Study on ALXN1850 for Adolescents and Adults with Hypophosphatasia Not Previously Treated with Asfotase Alfa

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALXN1850
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen - Cilag International

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Stockerau

What the registry says about research in the country

01 Metabolic Health Studies

Innovative research focusing on obesity and cardiovascular health, examining new therapeutic approaches for weight management and associated cardiovascular risks.

  • Cardiovascular Safety Assessment
  • Weight Management
  • Metabolic Disease Prevention

Studies aim to evaluate cardiovascular outcomes in individuals with overweight or obesity conditions.

02 Autoimmune Research

Clinical investigations targeting Sjögren's Syndrome, evaluating novel biological treatments to improve patient outcomes and disease management.

  • Disease Activity Assessment
  • Immunological Response
  • Symptom Management

Research focuses on measuring treatment efficacy through standardized disease activity scores.

03 Therapeutic Innovations

Advanced clinical research examining novel therapeutic compounds for chronic conditions, with emphasis on safety and efficacy measurements.

  • Drug Safety Profiles
  • Treatment Effectiveness
  • Patient Response Monitoring

Studies incorporate comprehensive safety monitoring and outcome assessment protocols.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.